Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
cRAF inhibitor
DRUG CLASS:
cRAF inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
encorafenib (63)
avutometinib (27)
ERAS-254 (7)
RAF709 (3)
donafenib (2)
BMS-908662 (0)
encorafenib (63)
avutometinib (27)
ERAS-254 (7)
RAF709 (3)
donafenib (2)
BMS-908662 (0)
›
Associations
(102)
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
cetuximab + binimetinib + encorafenib
Sensitive: A1 - Approval
cetuximab + binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
cetuximab + encorafenib
Sensitive: A1 - Approval
cetuximab + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Non Small Cell Lung Cancer
BRAF V600E
Non Small Cell Lung Cancer
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
BRAF V600E
Cutaneous Melanoma
BRAF V600E
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
cetuximab + encorafenib
Sensitive: A2 - Guideline
cetuximab + encorafenib
Sensitive
:
A2
BRAF V600
Rectal Cancer
BRAF V600
Rectal Cancer
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
panitumumab + encorafenib
Sensitive: A2 - Guideline
panitumumab + encorafenib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.